Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04310163 · ClinicalTrials.gov registry record
Interviews and Video Capture in Patients With GM1 Gangliosidosis
A clinical trial of GM1 Gangliosidosis, sponsored by LYSOGENE.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT04310163 is a study of GM1 Gangliosidosis that has completed, run by LYSOGENE. The registered enrollment target is 25 participants, below the 103-participant average among 6 other GM1 Gangliosidosis trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04310163, a study of GM1 Gangliosidosis, has completed, sponsored by LYSOGENE.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
GM1 gangliosidosis is a rare disease for which there is a limited understanding of disease progression and meaningful outcome measures. In addition, parents report that clinic-based assessments are not always well-suited to capture all the disease features and other metrics that have an impact on the patient and family. To address the methodological challenges of this small, heterogeneous population, this study will collect patient-specific home-based video data and qualitative interviews with caregivers.
Conditions Studied
Interventions
- OTHER Natural history
Study Locations (1)
Massachusetts
- Casimir Trials - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2023-05-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04310163
The ClinicalTrials.gov registry entry for NCT04310163 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 6 other GM1 Gangliosidosis trials with a reported enrollment target (76% lower). The listed sponsor is LYSOGENE, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GM1 Gangliosidosis appearing as the primary indexed condition, and to 1 intervention - of which Natural history is the first listed.
NCT04310163 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04310163 about?
NCT04310163 is a clinical study titled "Interviews and Video Capture in Patients With GM1 Gangliosidosis". GM1 gangliosidosis is a rare disease for which there is a limited understanding of disease progression and meaningful outcome measures. In addition, parents report that clinic-based assessments are not always well-suited to capture all the disease features and other metrics that have an impact on th...
What is the current status of trial NCT04310163?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2020-04-20. Estimated completion is 2023-05-05.
What conditions does trial NCT04310163 study?
This clinical trial studies the following conditions: GM1 Gangliosidosis.
What interventions are being tested in trial NCT04310163?
The interventions under investigation include: Natural history (OTHER).
Who is sponsoring clinical trial NCT04310163?
This trial is sponsored by LYSOGENE, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04310163 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GM1 Gangliosidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
RECRUITING · Phase 3
-
A Natural History Study of the Gangliosidoses
RECRUITING
-
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
ACTIVE NOT RECRUITING · Phase 1
-
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
COMPLETED
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
-
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.